Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Julphar
Merck
US Army
Queensland Health
Federal Trade Commission
Accenture
Cipla
Medtronic

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,512,297

« Back to Dashboard

Which drugs does patent 8,512,297 protect, and when does it expire?


Patent 8,512,297 protects APIDRA SOLOSTAR, TOUJEO SOLOSTAR, SOLIQUA 100/33, and LANTUS SOLOSTAR, and is included in four NDAs.

This patent has one hundred and forty patent family members in twenty-seven countries.

Summary for Patent: 8,512,297

Title:Pen-type injector
Abstract: The present invention relates to injectors, such as pen-type injectors, that provide for administration of medicinal products from a multidose-cartridge and permit a user to set the delivery dose. The injector may include a housing, a piston rod adapted to operate through the housing, a dose dial sleeve located between the housing and the piston rod, and a drive sleeve located between the dose dial sleeve and the piston rod. The dose dial sleeve may have a helical thread of first lead and the drive sleeve may have a helical groove of second lead. The first lead of the helical thread and the second lead of the helical groove may be the same.
Inventor(s): Veasey; Robert Frederick (Warwickshire, GB), Perkins; Robert (Warwickshire, GB), Plumptre; David Aubrey (Worcestershire, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (DE)
Application Number:13/040,198
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
APIDRA SOLOSTAR
insulin glulisine recombinant
INJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo► Subscribe► SubscribeY
Sanofi Us Services
TOUJEO SOLOSTAR
insulin glargine recombinant
SOLUTION;SUBCUTANEOUS206538-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY
Sanofi-aventis Us
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY
Sanofi Aventis Us
LANTUS SOLOSTAR
insulin glargine recombinant
INJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,512,297

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0304822.0Mar 03, 2003

Non-Orange Book Patents for Patent: 8,512,297

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,623,189Relating to drive mechanisms suitable for use in drug delivery devices► Subscribe
7,935,088Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,028,454Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,992,486Pen-type injector► Subscribe
8,876,782Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,233,211Relating to a pen-type injector► Subscribe
7,553,299Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,556,864Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,533,105Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,610,409Drive mechanisms suitable for use in drug delivery devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,512,297

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI341739► Subscribe
Taiwan200510026► Subscribe
TaiwanI340654► Subscribe
Taiwan200505521► Subscribe
TaiwanI336237► Subscribe
Taiwan200507897► Subscribe
TaiwanI323180► Subscribe
Taiwan200505522► Subscribe
Slovenia2281592► Subscribe
Slovenia2266648► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Farmers Insurance
Johnson and Johnson
UBS
Chubb
Argus Health
Harvard Business School
Fish and Richardson
US Department of Justice
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot